Company Encyclopedia
View More
name
Cowin Biotech
688426.SH
Jiangsu CoWin Biotech Co., Ltd. engages in the research and development, production, and sale of biological products in China. The company provides molecular diagnostic raw material enzymes, nucleic acid collection and protection agents, nucleic acid extraction and purification kits, molecular diagnostic testing reagents, etc. It also offers medical device products, nucleic acid collection and protection, PCR, RT-PCR, and qPCR products, molecular diagnosis, isothermal amplification, nucleic acid mass spectrometry, next generation sequencing, nucleic acid extraction and purification, marker clone transfection, antibody, protein detection products, and scientific research instruments.
1.529 T
688426.SHMarket value -Rank by Market Cap -/-

Financial Score

30/12/2025 Update
C
BiotechnologyIndustry
Industry Ranking57/81
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-9.42%D
    • Profit Margin-82.39%E
    • Gross Margin45.87%B
  • Growth ScoreB
    • Revenue YoY41.46%A
    • Net Profit YoY4.70%C
    • Total Assets YoY-7.16%D
    • Net Assets YoY-9.06%D
  • Cash ScoreC
    • Cash Flow Margin-121.38%D
    • OCF YoY41.46%A
  • Operating ScoreE
    • Turnover0.1E
  • Debt ScoreA
    • Gearing Ratio9.14%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Cowin Biotech released its performance for the first three quarters, with a net loss attributable to the parent company of 76.16 million yuan

    According to the Zhitong Finance APP, Cowin Biotech disclosed its third-quarter report for 2025. The company achieved revenue of 140 million yuan in the first three quarters, a year-on-year increase of 42.01%; the net profit attributable to the parent company was a loss of 76.16 million yuan; the net profit excluding non-recurring gains and losses was a loss of 93.91 million yuan; basic earnings per share were -0.69 yuan

    Zhitong·
    SH
    688426
    -1.33%
    Zhitong·
    SH
    688426
    -1.33%

    Cowin Biotech: Plans to acquire minority shareholder equity in its controlling subsidiary for 17.885 million yuan

    Cowin Biotech plans to acquire 49% equity of its holding subsidiary Shanghai Haowei Tai Biotechnology Co., Ltd. for 17.885 million yuan, with the acquirer being the minority shareholder Shanghai Tianhao Biotechnology Co., Ltd. After the transaction, Haowei Tai will become a wholly-owned subsidiary, aiming to strengthen management, improve decision-making efficiency, and enhance profitability. The transaction has been approved by the board of directors and independent directors, and does not require approval from the shareholders' meeting

    Zhitong·
    SH
    688426
    -1.33%
    Zhitong·
    SH
    688426
    -1.33%

    Cowin Biotech released its first-quarter performance, with a net loss attributable to the parent company of 22.7434 million yuan, narrowing the loss

    According to the Zhitong Finance APP, Cowin Biotech released its first-quarter report for 2025. The company's first-quarter operating revenue was 43.0055 million yuan, a year-on-year increase of 49.31%; the net loss attributable to shareholders of the listed company was 22.7434 million yuan, a narrowed loss; the net loss attributable to shareholders of the listed company after deducting non-recurring gains and losses was 28.7706 million yuan, a narrowed loss; the basic loss per share was 0.21 yuan/share

    Zhitong·
    SH
    688426
    -1.33%
    Zhitong·
    SH
    688426
    -1.33%

    Cowin Biotech: Human Septin9, SDC2, and NDRG4 gene methylation detection kits have obtained Class III medical device registration certificates

    Cowin Biotech announced that its wholly-owned subsidiary Jiangsu Jianwei Diagnostic Technology Co., Ltd. has developed the Septin9, SDC2, and NDRG4 gene methylation detection kits, which have received the Class III medical device registration certificate issued by the National Medical Products Administration. This is the company's first Class III registration certificate in the field of colorectal cancer auxiliary diagnosis, enhancing its competitiveness in related testing and gastrointestinal system diagnostics, and actively promoting the company's sales and business expansion

    Zhitong·
    SH
    688426
    -1.33%
    Zhitong·
    SH
    688426
    -1.33%

    National People's Congress representative and Chairman of Cowin Biotech, Wang Chunxiang: Suggests incorporating the monitoring of antimicrobial resistance of pathogenic microorganisms into the national public health system

    National People's Congress representative and Chairman of Cowin Biotech, Wang Chunxiang, suggested incorporating the monitoring of antimicrobial resistance of pathogenic microorganisms into the national public health system to address the resistance issues arising from antibiotic use. She emphasized the importance of establishing a monitoring system for the rational use of antibiotics and safeguarding public health. At the same time, Cowin Biotech plans to transform into a full-cycle health management service provider, offering technical support from pathogen identification to early cancer screening, contributing to the national cancer prevention and control and public health

    Zhitong·
    SH
    688426
    -1.33%
    Zhitong·
    SH
    688426
    -1.33%
    © 2025 Longbridge｜Disclaimer